Merck has signed a collaboration agreement with Iktos to deploy the AI specialist’s generative modelling technology to exacerbate the discovery and design of new compounds. Iktos’ technology automatically designs virtual novel molecules that have activities for treating specific diseases. This addresses the challenge of quickly identifying molecules that also satisfy criteria for clinical testing. The latest deal follows Merck's recent one-year licensing agreement with research and development firm Cyclica to use AI to identify drug targets and anticipate possible side effects. “AI-based machine learning is an exciting tool in our arsenal as we seek to develop innovative medicines based on natural products,” said Dr. David J. Anderson, CEO of Merck.http://www.cbc.@@
Merck has signed a collaboration agreement with Iktos to deploy the AI specialist’s generative modelling technology to exacerbate the discovery and design of new compounds. Iktos’ technology automatically designs virtual novel molecules that have activities for treating specific diseases. This addresses the challenge of quickly identifying molecules that also satisfy criteria for clinical testing. The latest deal follows Merck's recent one-year licensing agreement with research and development firm Cyclica to use AI to identify drug targets and anticipate possible side effects. Merck said the use of AI could lead to patients being given faster access to novel treatments.